Abstract
Asthma is an increasingly common chronic disease in children, accounting for more hospitalizations than many other chronic health conditions.1 Omalizumab is used to treat severe allergic asthma in children 6 years and older and improves asthma control and reduces asthma exacerbations and health care utilization as early as 16 weeks into treatment.2,3 Omalizumab dosing guidelines are dependent on serum immunoglobulin E (IgE) level and body weight and were designed to produce serum free IgE levels of 25 ng/mL or lower, which was associated with improved outcomes in clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
